晚期头颈恶性肿瘤程序性细胞死亡蛋白1免疫治疗的临床研究述评

doi:10.7518/hxkq.2020.05.003

华西口腔医学杂志 ›› 2020, Vol. 38 ›› Issue (5): 489-494.doi: 10.7518/hxkq.2020.05.003

晚期头颈恶性肿瘤程序性细胞死亡蛋白1免疫治疗的临床研究述评

郭伟()

上海交通大学医学院附属第九人民医院·口腔医学院口腔颌面头颈肿瘤科,国家口腔疾病临床医学研究中心,上海市口腔医学重点实验室,上海 200011

收稿日期:2020-03-08 修回日期:2020-07-18 出版日期:2020-10-01 发布日期:2020-10-14
通讯作者: 郭伟 E-mail:guoweicn@sohu.com
作者简介:郭伟,教授,博士,E-mail：guoweicn@sohu.com, 二级教授，博士生导师。从事口腔颌面头颈肿瘤的临床与基础研究逾30年。尤其对晚期口腔、口咽癌、黏膜黑色素瘤的免疫靶向个体化综合序列治疗进行了深入探索。诊治晚期肿瘤患者5 000余例。先后2次得到国家自然科学基金和国家重点研发计划资助。现任中国抗癌协会口腔颌面肿瘤整合医学专业委员会主任委员，亚洲冷冻治疗学会常委，上海抗癌协会肿瘤免疫治疗专委会副主任委员，NCCN中国版《头颈肿瘤临床实践指南》编委，上海市口腔医学会中西医结合专委会主任委员。主持国家级《口腔颌面肿瘤综合序列治疗》继续医学教育讲习班14届，领衔制定了《中国头颈黏膜黑色素瘤临床诊治专家共识》及《口腔颌面头颈部鳞癌超声热化疗中国专家共识》。近年作为项目负责人承担了国内外多项临床注册或Ⅰ期多中心临床试验。
基金资助:
上海市科委科研资助项目(11495802000);上海市科委科研资助项目(14D1941400);上海市科委科研资助项目(10410711200);上海市科委科研资助项目(140902100)

Clinical comment of programmed cell death protein 1 immunotherapy for advanced head and neck cancer

Guo Wei()

Dept. of Oral Maxillofacial and Head & Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine, College of Stomatology; National Clinical Research Center for Oral Disease; Shanghai Reaesrch Institute of Stomatology, Shang?hai 200011, China

Received:2020-03-08 Revised:2020-07-18 Online:2020-10-01 Published:2020-10-14
Contact: Guo Wei E-mail:guoweicn@sohu.com
Supported by:
The Project of Science and Technology Commission of Shanghai Municipality(11495802000);The Project of Science and Technology Commission of Shanghai Municipality(14D1941400);The Project of Science and Technology Commission of Shanghai Municipality(10410711200);The Project of Science and Technology Commission of Shanghai Municipality(140902100)

摘要/Abstract

摘要：

程序性细胞死亡蛋白1（PD-1）单抗是近年来恶性肿瘤治疗领域具有里程碑意义的药物,PD-1单抗的出现使免疫治疗迅速成为各种恶性肿瘤治疗的新选择。国外大量临床研究已充分证实其在晚期头颈癌的治疗中具有较传统治疗方案更加显著的疗效,同时具有低于细胞毒性药物的不良反应发生率。近期PD-1单抗类药物进入我国临床应用,改变了传统头颈部恶性肿瘤的治疗模式,免疫治疗已经成为复发/转移晚期头颈癌的一线治疗选择。目前,PD-1单抗类药物通过临床试验对其适应证进行不断拓展,同时也在对其生物标志物进行探索和验证。随着研究不断深入,PD-1单抗类药物的应用将趋于个体化、精准化,与传统疗法的联合应用有待临床进一步大样本多中心随机研究的印证。

关键词: 晚期头颈恶性肿瘤, 程序性细胞死亡蛋白1单抗, 免疫治疗

Abstract:

Anti-programmed cell death protein 1 (PD-1) monoclonal antibody is a landmark drug in the field of malignant tumor treatment, and its emergence has resulted in the use of immunotherapy in treating various types of malignancies. A large number of clinical studies abroad have shown that it has a more significant effect than traditional strategies in the treatment of advanced head and neck cancer, and it has a significantly lower incidence of adverse events than chemotherapy. Recently, the clinical application of anti-PD-1 monoclonal antibodies in China has changed the traditional treatment mode of head and neck malignant tumors. Immunotherapy has become the first-line treatment option for recurrent/metastatic head and neck cancer. Furthermore, the indications of PD-1 monoclonal antibodies have been continuously expanded through clinical trials, and their biomarkers have been explored and validated. The application of PD-1 monoclonal antibodies tend to be individualized and precise and potentially improves the treatment levels of advanced head and neck malignancies.

Key words: advanced head and neck cancer, anti-programmed cell death protein 1 monoclonal antibody, immunotherapy

中图分类号:

R739.8

郭伟. 晚期头颈恶性肿瘤程序性细胞死亡蛋白1免疫治疗的临床研究述评[J]. 华西口腔医学杂志, 2020, 38(5): 489-494.

Guo Wei. Clinical comment of programmed cell death protein 1 immunotherapy for advanced head and neck cancer[J]. West China Journal of Stomatology, 2020, 38(5): 489-494.

图/表 1

参考文献 33

[1]	Cramer JD, Burtness B, Ferris RL . Immunotherapy for head and neck cancer: recent advances and future directions[J]. Oral Oncol, 2019,99:104460. doi: 10.1016/j.oraloncology.2019.104460 URL pmid: 31683169
[2]	Burtness B, Harrington KJ, Greil R , et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study[J]. Lancet, 2019,394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7 URL pmid: 31679945
[3]	Ferris RL, Blumenschein G Jr, Fayette J , et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck[J]. N Engl J Med, 2016,375(19):1856-1867. doi: 10.1056/NEJMoa1602252 URL pmid: 27718784
[4]	Cohen EEW, Soulières D, Le Tourneau C , et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study[J]. Lancet, 2019,393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8 URL pmid: 30509740
[5]	Seiwert TY, Burtness B, Mehra R , et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial[J]. Lancet Oncol, 2016,17(7):956-965. doi: 10.1016/S1470-2045(16)30066-3 URL pmid: 27247226
[6]	Ferris RL, Blumenschein G Jr, Fayette J , et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression[J]. Oral Oncol, 2018,81:45-51. doi: 10.1016/j.oraloncology.2018.04.008 URL pmid: 29884413
[7]	Yearley JH, Gibson C, Yu N , et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer[J]. Clin Cancer Res, 2017,23(12):3158-3167. doi: 10.1158/1078-0432.CCR-16-1761 URL pmid: 28619999
[8]	Rizvi NA, Hellmann MD, Snyder A , et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015,348(6230):124-128. doi: 10.1126/science.aaa1348 URL pmid: 25765070
[9]	Lawrence MS, Stojanov P, Polak P , et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes[J]. Nature, 2013,499(7457):214-218. doi: 10.1038/nature12213 URL pmid: 23770567
[10]	Gameiro SF, Ghasemi F, Barrett JW , et al. Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy[J]. Oncoimmunology, 2018,7(10):e1498439. doi: 10.1080/2162402X.2018.1498439 URL pmid: 30288365
[11]	Harrington KJ, Ferris RL, Blumenschein G Jr , et al. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial[J]. Lancet Oncol, 2017,18(8):1104-1115. doi: 10.1016/S1470-2045(17)30421-7 URL pmid: 28651929
[12]	Wang DY, Salem JE, Cohen JV , et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis[J]. JAMA Oncol, 2018,4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923 URL pmid: 30242316
[13]	Johnson DB, Balko JM, Compton ML , et al. Fulminant myocarditis with combination immune checkpoint blockade[J]. N Engl J Med, 2016,375(18):1749-1755. doi: 10.1056/NEJMoa1609214 URL pmid: 27806233
[14]	Di Giacomo AM, Danielli R, Guidoboni M , et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases[J]. Cancer Immunol Immunother, 2009,58(8):1297-1306. doi: 10.1007/s00262-008-0642-y URL pmid: 19139884
[15]	Chiou VL, Burotto M . Pseudoprogression and immune-related response in solid tumors[J]. J Clin Oncol, 2015,33(31):3541-3543. doi: 10.1200/JCO.2015.61.6870 URL pmid: 26261262
[16]	Eisenhauer EA, Therasse P, Bogaerts J , et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009,45(2):228-247. doi: 10.1016/j.ejca.2008.10.026 URL
[17]	Baxi SS, Dunn LA, Burtness BA . Amidst the excitement: a cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma[J]. Oral Oncol, 2016,62:147-148. doi: 10.1016/j.oraloncology.2016.10.007 URL pmid: 27776933
[18]	Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria[J]. Clin Cancer Res, 2009,15(23):7412-7420. doi: 10.1158/1078-0432.CCR-09-1624 URL pmid: 19934295
[19]	Seymour L, Bogaerts J, Perrone A , et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics[J]. Lancet Oncol, 2017,18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8 URL pmid: 28271869
[20]	Tazdait M, Mezquita L, Lahmar J , et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria[J]. Eur J Cancer, 2018,88:38-47. doi: 10.1016/j.ejca.2017.10.017 URL pmid: 29182990
[21]	Le Lay J, Jarraya H, Lebellec L , et al. irRECIST and iRECIST: the devil is in the details[J]. Ann Oncol, 2017,28(7):1676-1678. doi: 10.1093/annonc/mdx168 URL pmid: 28383646
[22]	Xiang JJ, Uy NF, Minja FJ , et al. Hyperprogression after one dose of nivolumab in sinonasal cancer: a case report[J]. Laryngoscope, 2020,130(4):907-910. doi: 10.1002/lary.28042 URL pmid: 31058321
[23]	Champiat S, Dercle L, Ammari S , et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1[J]. Clin Cancer Res, 2017,23(8):1920-1928. doi: 10.1158/1078-0432.CCR-16-1741 URL pmid: 27827313
[24]	Saâda-Bouzid E, Defaucheux C, Karabajakian A , et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma[J]. Ann Oncol, 2017,28(7):1605-1611. doi: 10.1093/annonc/mdx178 URL pmid: 28419181
[25]	Keam SJ . Toripalimab: first global approval[J]. Drugs, 2019,79(5):573-578. doi: 10.1007/s40265-019-01076-2 URL pmid: 30805896
[26]	Tang B, Yan X, Sheng X , et al. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients[J]. J Hematol Oncol, 2019,12(1):7. doi: 10.1186/s13045-018-0693-2 URL pmid: 30642373
[27]	Sheng X, Yan X, Chi Z , et al. Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase Ⅰb trial[J]. J Clin Oncol, 2019,37(32):2987-2999. doi: 10.1200/JCO.19.00210 URL pmid: 31403867
[28]	Wang F, Wei XL, Wang FH , et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ⅰb/Ⅱ clinical trial NCT02915432[J]. Ann Oncol, 2019,30(9):1479-1486. doi: 10.1093/annonc/mdz197 URL pmid: 31236579
[29]	Hoy SM . Sintilimab: first global approval[J]. Drugs, 2019,79(3):341-346. doi: 10.1007/s40265-019-1066-z URL pmid: 30742278
[30]	Markham A, Keam SJ . Camrelizumab: first global approval[J]. Drugs, 2019,79(12):1355-1361. doi: 10.1007/s40265-019-01167-0 URL pmid: 31313098
[31]	Chen X, Ma L, Wang X , et al. Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210[J]. Cancer Biol Med, 2019,16(1):173-181. doi: 10.20892/j.issn.2095-3941.2018.0172 URL pmid: 31119058
[32]	Lin C, Wang S, Xie W , et al. Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway[J]. Oncotarget, 2016,7(37):59236-59244. doi: 10.18632/oncotarget.10985 URL pmid: 27494860
[33]	Xu J, Zhang Y, Jia R , et al. Anti-PD-1 Antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study[J]. Clin Cancer Res, 2019,25(2):515-523. doi: 10.1158/1078-0432.CCR-18-2484 URL pmid: 30348638

姓名	性别	年龄/岁	诊断	用药次数	近期疗效
孙XX	男	52	肺癌舌转移	4	疾病稳定
王X	男	35	右下牙龈黑色素瘤远处转移	1	死亡
熊XX	男	59	左腮腺癌颈部转移	3	死亡
刘XX	女	52	左颌下腺腺样囊性癌肺部转移	6	疾病稳定
宋XX	女	65	下牙龈黏膜黑色素瘤肺部转移	5	疾病稳定
张XX	女	42	颌骨肉瘤术后、放疗后复发	4	疾病进展
陶XX	男	47	腮腺导管癌术后放疗后骨转移	6	疾病进展
尹XX	男	57	颞部鳞状细胞癌多次术后复发	4	完全缓解
徐XX	男	49	鼻腔鼻窦恶性黑色素瘤远处转移	4	疾病稳定
苏XX	女	35	上前牙龈恶性黑色素瘤颈部转移	12	部分缓解

晚期头颈恶性肿瘤程序性细胞死亡蛋白1免疫治疗的临床研究述评

Clinical comment of programmed cell death protein 1 immunotherapy for advanced head and neck cancer

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 33

相关文章 2

编辑推荐

Metrics

本文评价

[1]	刘磊, 向中正, 李一, 郭伟, 杨凯, 王军, 孙志军, 任国欣, 张建国, 孙沫逸, 冉伟, 黄桂林, 唐瞻贵, 李龙江. 头颈部鳞癌免疫检查点抑制剂治疗专家共识[J]. 华西口腔医学杂志, 2022, 40(6): 619-628.
[2]	郅克谦徐燕任文豪高岭赵璐杨勇张引成. 不同方法制备抗原致敏的树突状细胞介导T淋巴细胞对Tca8113细胞杀伤作用的影响[J]. 华西口腔医学杂志, 2010, 28(02): 195-198.